anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The incidence of ischemic stroke is increasing year by year and showing a younger trend. Impaired blood-brain barrier (BBB) is one of the pathological manifestations caused by cerebral ischemia, leading to poor prognosis of patients. Accumulating evidence indicates that ferroptosis is involved in cerebral ischemia/reperfusion injury (CIRI). We have previously demonstrated that Ginsenoside Rd (G-Rd) protects against CIRI-induced neuronal injury. However, whether G-Rd can attenuate CIRI-induced disruption of the BBB remains unclear. In this study, we found that G-Rd could upregulate the levels of ZO-1, occludin, and claudin-5 in ipsilateral cerebral microvessels and bEnd.3 cells, reduce endothelial cells (ECs) loss and Evans blue (EB) leakage, and ultimately improve BBB integrity after CIRI. Interestingly, the expressions of ACSL4 and COX2 were upregulated, the expressions of GPX4 and xCT were downregulated, the levels of GSH was decreased, and the levels of MDA and Fe2+ were increased in ischemic tissues and bEnd.3 cells after CIRI, suggesting that ECs ferroptosis occurred after CIRI. However, G-Rd can alleviate CIRI-induced BBB disruption by inhibiting ECs ferroptosis. Mechanistically, G-Rd prevented tight junction loss and BBB leakage by upregulating NRG1, activating its tyrosine kinase ErbB4 receptor, and then activating downstream PI3K/Akt/mTOR signaling, thereby inhibiting CIRI-induced ferroptosis in ECs. Taken together, these data provides data support for G-Rd as a promising therapeutic drug for cerebral ischemia.
Surgical staplers have been utilized in colorectal procedures since the early 20th century, with intraluminal staplers used to create the anastomosis since 1979. Successful utilization of these devices, whether in open or laparoscopic procedures, requires extensive training and experience. Even with experience, device issues such as stapler misfire, incomplete firing, low surgeon satisfaction, etc., may occur. In a retrospective study of 349 colorectal resections, 67 (19%) procedures had some type of technical error. The most frequently reported issues from the analysis were positive leak tests, difficulty placing or removing the stapler, and inadequate donuts. Surgeons may also experience psychological or physical stress during procedures due to complications, workload, or other factors.

Patients scheduled to undergo a left-sided colon resection, and who meet study entry criteria, may be enrolled. Investigators will perform each procedure using the powered circular stapler according to the instructions for use (IFU). There will be no blinding or planned-interim analysis. Procedures may be performed open or via minimally invasive surgery (MIS) according to institutional standard-of-care (SOC). Use of a hand port and robotic assistance are permissible providing the powered circular stapler is used to create the anastomosis. Conversion from laparoscopic to open surgery is permissible under the protocol at the surgeon's discretion for the patient's safety.

The final scheduled study visit will occur 28 days post-procedure (routinely scheduled follow-up with surgeon). Follow-up by phone is permissible when an on-site visit is not planned or is more than six weeks post-operative.
Provided is a cosmetic composition having structural recoverability and a good feel when used, which is transparent and smooth when applied to the skin or hair. The cosmetic composition comprises components (A) to (D) in amounts such that the composition includes 0.1-30 mass% of component (A), 0.1-50 mass% of component (B), 50-95 mass% of component (C), and 0.01-10 mass% of component (D), with the mass ratio of component (A) to component (B) being in the range of 1/5-5/1. (A) is a polyalkylene glycol derivative represented by the formula Z-{O-(EO) a -(AO) k -H} m  (where Z is a polyalcohol residue having 3-6 hydroxyl groups, EO is an oxyethylene group, AO is a C4-8 oxyalkylene group, and EO and AO are bonded in a block-form). (B) is a nonionic surfactant which has a polyoxyethylene group and a C12-22 hydrocarbon group, and exhibits an HLB of 8-14. (C) is at least one lubricant selected from among ester oils that are liquid at 25˚C and triglycerides. (D) is water.
Morbidity and premature mortality from noncommunicable diseases can be largely prevented by adopting a healthy lifestyle at the earliest possible age. However, tools designed for the early identification of those at risk among young adults are lacking. We developed and validated a multivariable model for the prediction of life expectancy, allowing the early identification of apparently healthy adults at risk of lifestyle-related diseases. We used a cross-sectional approach to calculate life expectancy using data from 38,481 participants of the National Health and Nutrition Examination Survey (1999-2014), aged ≥20 years. A multivariable logistic model was used to quantify the impact of risk factors on mortality. The model included the following lifestyle-related mortality risk factors as predictors: smoking, diet, physical activity, and body mass index. The presence of the following chronic diseases was considered: diabetes, arrhythmia, coronary artery disease, myocardial infarction, stroke, and malignant neoplasms. The model showed a good predictive ability; the area under the receiver operating characteristic curve measure was 0.846 (95% uncertainty interval 0.838-0.859). Life expectancy was determined using the life table method and the period life tables for the US population as the baseline. The results of this model underscore the importance of lifestyle-related risk factors in life expectancy. The difference between life expectancy for 30-year-old individuals with lifestyle characteristics ranked in 90% and 10% of their gender and age groups was 23 years for males and 18 years for females, whereas in 75% and 25%, it was 14 years for males and 10 years for females. In addition to early risk identification, the model estimates the deferred effect of lifestyle and the impact of lifestyle changes on life expectancy. Thus, it can be used in early prevention to demonstrate the potential risks and benefits of complex lifestyle modifications for educational purposes or to motivate behavioral changes.
OBJECTIVE: Patients with gout are at elevated risk of multiple vascular and metabolic comorbidities. Whether they are also at risk of sarcopenia, which is known to affect patients with other rheumatic diseases, has not been previously assessed. We examined whether patients with gout have decreased lumbar muscle quality and quantity, indicating an association between gout and sarcopenia.
METHODS: Fifty gout subjects and 25 controls, ages 45-80, underwent computed tomography imaging of the lumbosacral spine. We measured muscle quantity (skeletal muscle area [SMA] and index [SMI]) and quality (skeletal muscle radiation attenuation [SMRA] and intermuscular adipose tissue [IMAT] area and index [IMATI]) of the psoas and erector spinae muscles at the L3 level.
RESULTS: Seventy subjects (45 gout and 25 controls) were included in the analysis. Gout subjects had higher BMI, more kidney disease and hypertension, lower exercise frequency, and higher mean serum urate and creatinine vs. controls. Lumbar SMRA was significantly lower in gout subjects vs. controls, indicating reduced muscle quality. Lumbar IMAT area was significantly higher in gout subjects vs. controls, as was lumbar IMATI, indicating increased muscle adiposity. These differences persisted after adjusting for potential confounders. In contrast, there was no significant difference between gout and control groups in lumbar SMA or lumbar SMI, suggesting that muscle quantity may not be routinely affected by the diagnosis of gout.
CONCLUSIONS: Gout patients exhibit decreased lumbar muscle quality compared with controls, consistent with an association between gout and sarcopenia.
The invention relates to a composition comprising a RNA sequence encoding the SARS-CoV-2 S protein of the Omicron variant or an immunogenic fragment thereof. Preferably the protein comprises the S1 subunit or the receptor binding domain (RBD) of the S protein. The Omicron variant could be BA.4, BA.5, BA.1, BA.2, XBB, XBB.1 or BQ.1.1. The composition is an immunogenic composition and further comprises lipid nanoparticles, modified uridines, a poly-A sequence and a linker. The immunogenic composition comprises a first and second RNA which can be formulated in separate or the same lipid nanoparticles. The immunogenic composition is used to induce immune response against SARS-CoV-2 in a subject, the response can be against Omicron, Beta, Alpha or Delta variants or the Wuhan strain. Also disclosed is an antigen that is not a BA.1 Omicron variant of SARS-CoV-2. An immunogenic composition comprising a first RNA encoding a SARS-CoV-2 S protein of a Wuhan strain, an Alpha, Beta or Delta variant and a second RNA that isn’t a BA.1 Omicron variant. An immunogenic composition comprising a first RNA encoding a SARS-CoV-2 S protein of a Wuhan strain, an Alpha, Beta, Delta or BA.1 variant and a second RNA which is antigenically distinct.
For the first week of the 8 week treatment period, patients received aliskiren 150 mg, placebo to aliskiren, and 2 capsules of placebo to valsartan. For the remaining 7 weeks of the study, patients received aliskiren 300 mg (two 150 mg tablets) and 2 capsules of placebo to valsartan. The tablets and capsules (2 of each) were taken orally once daily each morning. To evaluate a missed dose, the last dose of medication was administered at the clinic, and the patient was scheduled to return 2 days later for exercise testing (8 weeks + 2 days).
PURPOSE: Storytelling is an integral part of human life, providing opportunities for social closeness, relationship development, and identity exploration. Having aphasia can disrupt the ability to convey stories across a variety of settings. Structured songwriting frameworks may provide people with aphasia an opportunity to successfully engage in this medium for storytelling.
METHOD: Three individuals with aphasia participated in a structured songwriting intervention modified to support individuals with aphasia. Each participant-songwriter co-constructed three songs about their life in collaboration with an interdisciplinary team. Data about the songwriting process were collected via individual semi-structured qualitative interview and analysed using interpretative phenomenological analysis to identify superordinate themes and subthemes.
RESULT: The overarching superordinate theme related to the process itself as a catalyst that occurred as a result of participating in a songwriting intervention modified for individuals with aphasia. Three subthemes were identified: (a) relationship-centred experience, (b) engagement in meaningful activities, and (c) identity exploration.
CONCLUSION: Songwriting may provide meaningful opportunities for people with aphasia to experience the power of sharing stories about themselves. Key components of this experience aligned with the core elements of the positive psychology PERMA (Positive Emotion, Engagement, Relationships, Meaning, and Accomplishments) framework. Findings support incorporating storytelling through songwriting into the rehabilitation journey for individuals with aphasia.
PURPOSE:To obtain an emulsified dispersion with high stability, storage stability, etc. by using modified PVA prepd. by saponifying a copolymer consisting of the specific three components as an emulsifying and dispersing agent for lipophilic nonaqueous materials. CONSTITUTION:The modified PVA prepd. by saponifying the copolymer of the three components; a monomer such as vinyl ester of fatty acid of >=5 carbon numbers such as vinyl valerate, vinyl ether of alkyl groups of >=4 carbon numbers such as butyl vinyl ether or the like, the monomer of the general formulaI (where R1=H or a lower alkyl group, R2= an alkyl group, R3-5=H or an alkyl  group, M= one equiv. of hydrogen or cation) and vinyl acetate is used as an  emulsifying and dispersing agent for liphophilic nonaqueous materials. The resultant emulsifying and dispersing agent has high stability, and outstanding  storage stability, mechanical properties, etc.
Digestive absorption of nutrients in an animal is increased by admin. to the animal of a material (I), esp. an antimotility agent, to increase the dwell time of nutrient matter in the digestive tract. Admin. of (I) is for a sufficiently long period for increased digestion and absorption of the nutrients. - Increased digestive absorption of nutrients in animals causes an increase in the feed efficiency of the animals, esp. in the meat, poultry, dairy and cultivated fishing industries. The feed is efficiently utilised while adverse side effects associated with the usual growth promotants are avoided, and the feed consumption is decreased, with reduced waste generation. The period of growth from infancy to maturity in the animals is shortened. (I) is included in feed to provide 0.005-0.5 mg/kg daily. (Provisional Basic previously advised in Week E42) USAB- US4562209 A Improved feed efficiency for animal population of poultry, comprises administering 0.01-0.1 mg. per kg. of amidinourea of formula (I) or its edible salts, which increases the dwell time of nutrient matter in the digestive tract, w.r.t. healthy animals. Admin. is over a time which increases digestion and absorption of nutrients over and above that which would have been effected had the animal not assimilated (I). - R1, R2, R3 and R4 are H, halo-lower alkyl, lower alkoxy, or lower alkyl R6 is H or lower alkyl R' and R'' are H, lower alkyl, lower alkoxy, halo, or halo-lower alkyl R is H, lower alkyl, halo, lower alkoxy, NO2, NH2, or halo-lower alkyl and n is 0-3.
Patients undergo collection of peripheral blood stem cells. Patients receive melphalan IV for 1 cycle and then 2 days later receive the stem cell transplant IV in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography at screening and at progression. Patients undergo bone marrow aspiration and biopsy within 60-90 days post initiation of stem cell transplant. Patients undergo blood and urine sample collection at screening, during treatment, and the end of treatment and during follow up or at progression.
The study will be a single dose, randomized, two-way crossover study in 40 healthy subjects, with equal numbers of males and females. Drop-outs will not be replaced. The two doses of medication given in the study (a single dose in each of the two study periods) will be separated by a washout period of at least 7 days. In each study period, sixteen blood samples for pharmacokinetic analysis will be taken over 24 hours. Blood samples will be centrifuged and concentrations of paracetamol and phenylephrine in plasma will be measured using a validated chromatographic assay. Pharmacokinetic parameters will be calculated from plasma concentration data. The rate and extent of absorption of the formulations will be compared.
The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency. They will also be asked to provide self reported data on their symptoms and their adherence at 3 points in time (start, mid-point, and end of trial).
There is disclosed a granular composition having particles of average particle size as determined by sieving in the range 70 to 500 microns, the said particles comprising up to 55% of active ingredient e.g. ferrous sulphate having primary particles the maximum dimension (A) of which as determined by microscopy is less than 50 microns and a particulate water soluble extender e.g. lactose having an average particle size (B) as determined by sieving in excess of 50 microns, the particles of active ingredient and water soluble extender being held in self-supporting spaced relationship by a water insoluble polymer film matrix e.g. of a polyacrylate polymer, providing the balance of the weight of the particle and being less than 50% by weight of the particle. The invention also extends to a blend convertible by pressure alone to a substantially continuous three-dimensional porous matrix substantially devoid of separate resin particles, of active ingredient/water soluble extender/resin particles, e.g. as above, in which the active ingredient comprises 45 to 60%, the water soluble extender comprises 35 to 45%, and the resin comprises 5 to 15% by weight and a water insoluble extending agent or filler for the matrix resin and a water soluble or insoluble tableting aid or lubricant, the active ingredient/water soluble extender/resin particles comprising 80 to 95%, the water insoluble extending agent or filler for the matrix resin comprising 5 to 15% and the lubricant 0.2 to 5% of the blend.
Signaling-dependent changes in protein phosphorylation are critical to enable coordination of transcription and metabolism during macrophage activation. However, the role of acetylation in signal transduction during macrophage activation remains obscure. Here, we identify the redox signaling regulator peroxiredoxin 1 (PRDX1) as a substrate of the lysine acetyltransferase MOF. MOF acetylates PRDX1 at lysine 197, preventing hyperoxidation and thus maintaining its activity under stress. PRDX1 K197ac responds to inflammatory signals, decreasing rapidly in mouse macrophages stimulated with bacterial lipopolysaccharides (LPSs) but not with interleukin (IL)-4 or IL-10. The LPS-induced decrease of PRDX1 K197ac elevates cellular hydrogen peroxide accumulation and augments ERK1/2, but not p38 or AKT, phosphorylation. Concomitantly, diminished PRDX1 K197ac stimulates glycolysis, potentiates H3 serine 28 phosphorylation, and ultimately enhances the production of pro-inflammatory mediators such as IL-6. Our work reveals a regulatory role for redox protein acetylation in signal transduction and coordinating metabolic and transcriptional programs during inflammatory macrophage activation.
An anti-microbial preservative for use in ophthalmic and dermatologic products. The preservative includes from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Additionally, the preservative does not generate chlorine dioxide within the pH range of 5.0-8.8. Also included are an antimicrobial ophthalmic and dermatologic compositions for direct application onto an eye or skin of a living being including from about 0.005 wt. % to about 0.20 wt. % chlorite compound and from about 0.005 wt. % to about 0.05 wt. % peroxy compound. Also included are methods for treating dryness of the eyes and skin disorders (e.g., wounds, burns, infections, ulcerations, psoriasis, etc.) and for disinfecting and cleansing contact lenses while in place upon an eye by applying the composition to the eye or to the contact lens.
On the day of the ACBT, the patient will be taught to place dental cotton swabs between the cheek and gum, as well as beneath the tongue, to absorb saliva and prevent contamination of the collected sputum by saliva. Throughout the treatment, the patient will be urged to maintain a comfortable sitting position. The patient will then be instructed to perform PLB at a normal tidal volume (for approximately 6 breaths), followed by 3-4 deep inspirations with relaxed exhalation (thoracic expansion exercise), and finally, another period of breathing control, i.e. PLB, followed by FET, i.e. a deep breath in and a huff cough, followed by a medium breath in and a huff cough again. Approximately thirty minutes will pass over the course of this session.
Non-surgical periodontal treatment will be applied to individuals with periodontitis, clinical measurements, saliva collection and gingival crevicular fluid will be repeated 12 weeks after the treatment. IL-39 analysis will be performed by ELISA in saliva and gingival crevicular fluid of individuals. IL-39 and cotinine levels will be examined to evaluate the effects of smoking before and after treatment in periodontal health and periodontitis. Clinical measurements (Plaque index, probing depth, gingival recession, clinical attachment level, bleeding on probing) and salivary sample will be taken from all individuals at the beginning of the study.
The present invention discloses a Chinese medicine for treating hepatitis B, which is mainly composed of bupleurum roots, gardenias, scutellaria roots, water plantain rhizomes, atractylodes rhizomes, amomun fruits, Sichuan rhizoma coptidis, curcuma roots, artemisiae scopariae, green tangerine peel, round cardamon seeds, barbat skullcap, vietnamese sophora roots, licorice, magnolia bark and saussureae roots. The present invention breaks through the existing compounding method only for treating hepatitis B by using Chinese medicines for treating hepatitis B. According to the pathogenic factors, the pathological mechanisms, the pathogenesis and the prognosis prediction of the hepatitis B, the medicine is integrally prepared. The present invention can be used for comprehensively treating diseases, and can treat both manifestation causes and root causes of the diseases. Curative ratio can reach above 90%, total effective rate is 100%, and treatment course is short. The present invention is an ideal Chinese medicine for treating the hepatitis B.
Both Lipiflow and iLux procedures were performed bilaterally on all subjects on the same day. Subjects were randomized to which procedure they received first. There was a 1-hour wait between procedures.
Bipolar affective disorder is a debilitating illness, and is characterized by depression episodes that dominates the longitudinal course and are most difficult to treat. Controlled trials with monotherapy mood stabilizers such as lithium and valproate show little to no efficacy and antidepressants may offer no additional efficacy. Recently there has been a growing interest in the use of quetiapine in bipolar depression. However, a successful treatment may take up to 8 weeks, and full remission is achieved in only 50% of patients. Thyroid hormone augmentation strategies have been used in unipolar depression with good results, but there is a paucity of its efficacy in bipolar depression (BD). To our knowledge there are no controlled studies regarding the efficacy of thyroid augmentation in BD. The present study proposes to evaluate the efficacy of T3 as an augmentation to treatment as usual in the treatment of BD. We plan to enroll patients with bipolar disorder I or II who are currently presenting with depressive symptoms. Patients will be randomized to 2 groups - liothyronine or placebo Results will provide information on the possible role of thyroid hormone augmentation in the treatment of patients with bipolar depression, and may contribute to alleviate the burden of this disabling condition.
Patients will receive a pre-operative blood transfusion. Those presenting with an admission Hb of less than 9g/dL will receive a simple (also called a 'top-up') transfusion, those presenting with an admission Hb of more than or equal to 9g/dL will undergo a partial exchange transfusion.
Clinician Erythema Assessment (CEA) and Patient Self-Assessment (PSA) scores, assessing severity of erythema, will be obtained prior to study treatment to confirm subject eligibility. Enrolled subjects will receive up to three dual-depth treatments to affected areas of the midface (cheeks, chin, forehead, glabella and nose) each treatment provided approximately 2 weeks apart. Groups A and B will receive low-density treatment, and Groups C and D receive high-density treatment. Groups A and C will receive 2 treatments. Groups B and D will receive 3 treatments. Protocol amended Sept 2014: Groups A and C will receive 1 treatment; Groups B and D will receive 2 treatments.
Pediatric subjects age 6-10 years receive single dose of 150 mg L9LS subcutaneously. Once subjects reach day 7 post-administration without safety concerns, dosing begins for arm 2.